AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
Additional_JJ
Information_NOMZ
140_CD
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
Additional_JJ
Information_NOMZ
History_NN
and_PHC
development_NOMZ
of_PIN
the_DT
Company_NN
Directors_NN
are_VPRT [PASS]
not_XX0
required_VBN [SUAV]
to_TO
retire_VB
at_PIN
a_DT
shareholders_NN
._.
All_QUAN
other_JJ
extraordinary_JJ
general_JJ
AstraZeneca_NN
PLC_NN
was_VBD [PASS]
incorporated_VBN
in_CONJ
particular_NULL
age_NN
._.
meetings_GER
require_VPRT [SUAV]
14_CD
clear_JJ
days_NN
notice_NN
._.
England_NN
and_PHC
Wales_NN
on_PIN
17_CD
June_NN
1992_CD
under_IN
the_DT
Companies_NN
Act_NN
1985_CD
._.
It_PIT
is_VPRT [BEMA]
a_DT
public_JJ
limited_JJ
Directors_NN
are_VPRT [PASS]
required_VBN [SUAV]
to_TO [SPIN]
beneficially_RB
own_VB
For_PIN
all_QUAN
general_JJ
meetings_GER
,_,
a_DT
quorum_NN
of_PIN
two_CD
company_NN
domiciled_VBD
in_PIN
the_DT
UK_NN
._.
The_DT
Ordinary_NN
Shares_NN
in_PIN
the_DT
Company_NN
of_PIN
an_DT
shareholders_NN
present_VPRT
in_PIN
person_NN
or_CC
by_PIN
proxy_NN
Companys_NN
registered_VBD
number_NN
is_VPRT [BEMA]
2723534_CD
aggregate_JJ
nominal_JJ
amount_NN
of_PIN
$_$
125_CD
._.
and_ANDC
its_PIT
registered_JJ
office_NN
is_VPRT [BEMA]
at_PIN
15_CD
Stanhope_NN
present_NN
,_,
this_DEMP
means_VPRT [PRIV] [THATD]
they_TPP3
must_NEMD
own_VB
at_PIN
least_JJ
Gate_NN
,_,
London_NN
W1K_NN
1LN_NN
telephone_NN
44_CD
500_CD
shares_NN
._.
Shareholders_NN
and_CC
their_TPP3
duly_RB
appointed_VBN
0_CD
20 7304 5000_CD
._.
From_PIN
February_NN
1993_CD
until_IN
proxies_NN
and_CC
corporate_JJ
representatives_NN
are_VPRT
April_NN
1999_CD
,_,
the_DT
Company_NN
was_VBD [PASS]
called_VBN
Zeneca_NN
Rights_NN
,_,
preferences_NN
and_PHC
restrictions_NOMZ
entitled_VBN
to_TO
be_VB [PASS]
admitted_VBN [PUBV]
to_PIN
general_JJ
meetings_GER
._.
On_PIN
6_CD
April_NN
1999_CD
,_,
the_DT
Company_NN
attaching_VBG [WZPRES]
to_PIN
shares_NN
changed_VBD
its_PIT
name_NN
to_PIN
AstraZeneca_NN
PLC._NN
._.
The_DT
share_NN
capital_NN
of_PIN
the_DT
Company_NN
is_VPRT [PASS]
divided_VBN
Limitations_NOMZ
on_PIN
the_DT
rights_NN
to_TO
own_VB
shares_NN
into_PIN
2,400,000,000_CD
Ordinary_NN
Shares_NN
with_PIN
a_DT
There_EX
are_VPRT
no_SYNE
limitations_NOMZ
on_PIN
the_DT
rights_NN
to_TO
own_VB
The_DT
Company_NN
was_VBD [PASS]
formed_VBN
when_RB
the_DT
nominal_JJ
value_NN
of_PIN
$_$
0.25_CD
each_QUAN
and_CC
50,000_CD
shares_NN
._.
pharmaceutical_JJ
,_,
agrochemical_NN
and_PHC
specialty_NN
Redeemable_JJ
Preference_NN
Shares_NN
with_PIN
a_DT
chemical_NN
businesses_NOMZ
of_PIN
Imperial_NN
Chemical_NN
nominal_JJ
value_NN
of_PIN
1.00_CD
each_QUAN
._.
The_DT
rights_NN
and_PHC
Industries_NN
PLC_NN
were_VBD [PASS]
demerged_VBN
in_PIN
1993_CD
._.
In_PIN
restrictions_NOMZ
attaching_VBG [WZPRES]
to_PIN
the_DT
Redeemable_JJ
1999_CD
,_,
the_DT
Company_NN
sold_VBD
the_DT
specialty_NN
Preference_NN
Shares_NN
differ_VPRT
from_PIN
those_DEMP
attaching_VBG
chemical_NN
business_NOMZ
._.
Also_RB
in_PIN
1999_CD
,_,
the_DT
to_PIN
Ordinary_NN
Shares_NN
as_IN
follows_VPRT
:_:
Company_NN
merged_VBD
with_PIN
Astra_NN
AB_NN
of_PIN
Sweden_NN
._.
In_PIN
2000_CD
,_,
it_PIT
demerged_VBD
the_DT
agrochemical_NN
the_DT
Redeemable_NN
Preference_NN
Shares_NN
carry_VPRT
business_NOMZ
and_CC
merged_VBD
it_PIT
with_PIN
the_DT
similar_JJ
no_SYNE
rights_NN
to_TO
receive_VB
dividends_NN
:_:
agribusiness_NOMZ
of_PIN
Novartis_NN
AG_NN
to_TO
form_VB
a_DT
new_JJ
company_NN
called_VBD
Syngenta_NN
AG_NN
._.
the_DT
holders_NN
of_PIN
Redeemable_JJ
Preference_NN
Shares_NN
have_VPRT
no_SYNE
rights_NN
to_TO
receive_VB
notices_NN
The_DT
Company_NN
owns_VPRT
and_PHC
operates_VPRT
numerous_JJ
of_PIN [STPR]
,_,
attend_VB
or_CC
vote_VB [SUAV]
at_PIN
general_JJ
meetings_GER
R&D_NN
,_,
production_NOMZ
and_PHC
marketing_GER
facilities_NOMZ
except_PIN
in_PIN
certain_JJ
limited_JJ
circumstances_NN
:_:
worldwide_NN
._.
Its_PIT
corporate_JJ
headquarters_NN
are_VPRT [BEMA]
at_PIN
they_TPP3
have_VPRT
one_CD
vote_NN
for_PIN
every_QUAN
50,000_CD
15_CD
Stanhope_NN
Gate_NN
,_,
London_NN
W1K_NN
1LN_NN
and_CC
its_PIT
Redeemable_JJ
Preference_NN
Shares_NN
held_VBD [PRIV]
:_:
R&D_NN
headquarters_NN
are_VPRT [BEMA]
at_PIN
SE-151_CD
85_CD
Sdertlje_NN
,_,
Sweden_NN
._.
on_PIN
a_DT
distribution_NOMZ
of_PIN
assets_NN
of_PIN
the_DT
Company_NN
,_,
on_PIN
a_DT
winding-up_NN
or_CC
other_JJ
Memorandum_NN
and_PHC
Articles_NN
of_PIN
Association_NOMZ
return_NN
of_PIN
capital_NN
subject_NN
to_PIN
certain_JJ
Objects_NN
exceptions_NOMZ
,_,
the_DT
holders_NN
of_PIN
Redeemable_JJ
As_IN
is_VPRT [BEMA]
typical_PRED
of_PIN
companies_NN
registered_VBN [WZPAST]
in_PIN
Preference_NN
Shares_NN
have_VPRT
priority_NOMZ
over_IN
the_DT
England_NN
and_PHC
Wales_NN
,_,
the_DT
Companys_NN
objects_NN
,_,
holders_NN
of_PIN
Ordinary_NN
Shares_NN
to_TO
receive_VB
the_DT
which_WDT
are_VPRT [PASS]
detailed_VBN
in_PIN
the_DT
Memorandum_NN
of_PIN
capital_NN
paid_VBN
up_RP
on_PIN
those_DEMO
shares_NN
:_:
and_ANDC
Association_NOMZ
,_,
are_VPRT [BEMA]
broad_PRED
and_PHC
wide-ranging_PRED
and_CC
include_VPRT
manufacturing_GER
,_,
distributing_VBG
and_CC
subject_JJ
to_PIN
the_DT
provisions_NN
of_PIN
the_DT
trading_GER
pharmaceutical_JJ
products_NN
._.
Companies_NN
Act_NN
1985_CD
,_,
the_DT
Company_NN
has_VPRT
the_DT
right_NN
to_TO
redeem_VB
the_DT
Redeemable_JJ
Directors_NN
Preference_NN
Shares_NN
at_PIN
any_QUAN
time_NN
on_PIN
giving_VBG
Subject_NN
to_PIN
certain_JJ
exceptions_NOMZ
,_,
Directors_NN
do_VPRT
not_XX0
less_JJ
than_PIN
seven_CD
days_NN
written_VBN [PUBV]
notice_NN
._.
not_XX0
have_VB
power_NN
to_TO
vote_VB [SUAV]
at_PIN
Board_NN
Meetings_GER
on_PIN
matters_NN
in_PIN
which_WDT [PIRE]
they_TPP3
have_VPRT
a_DT
material_NN
Action_NOMZ
necessary_JJ
to_TO
change_VB
the_DT
rights_NN
of_PIN
interest_NN
._.
shareholders_NN
In_PIN
order_NN
to_TO
vary_VB
the_DT
rights_NN
attached_VBN [WZPAST]
to_PIN
any_QUAN
The_DT
quorum_NN
for_PIN
meetings_GER
of_PIN
the_DT
Board_NN
of_PIN
class_NN
of_PIN
shares_NN
,_,
the_DT
consent_NN
in_PIN
writing_GER
of_PIN
the_DT
Directors_NN
is_VPRT [BEMA]
a_DT
majority_NOMZ
of_PIN
the_DT
full_JJ
Board_NN
,_,
of_PIN
holders_NN
of_PIN
three_CD
quarters_NN
in_PIN
nominal_JJ
value_NN
of_PIN
whom_WP [PIRE]
at_PIN
least_JJ
four_CD
must_NEMD
be_VB [BEMA]
Non-Executive_PRED
the_DT
issued_VBN
shares_NN
of_PIN
that_DEMO
class_NN
or_CC
the_DT
Directors_NN
._.
In_PIN
the_DT
absence_NN
of_PIN
a_DT
quorum_NN
,_,
the_DT
sanction_NOMZ
of_PIN
an_DT
extraordinary_JJ
resolution_NOMZ
Directors_NN
do_VPRT
not_XX0
have_VB
power_NN
to_TO
determine_VB [SUAV] [PRIV]
passed_VBN
at_PIN
a_DT
general_JJ
meeting_GER
of_PIN
such_JJ
holders_NN
compensation_NOMZ
arrangements_NOMZ
for_PIN
themselves_TPP3
is_VPRT [PASS]
required_VBN [SUAV]
._.
or_CC
any_QUAN
member_NN
of_PIN
the_DT
Board_NN
._.
Annual_JJ
general_JJ
meetings_GER
and_CC
The_DT
Board_NN
of_PIN
Directors_NN
may_POMD
exercise_VB
all_QUAN
the_DT
extraordinary_JJ
general_JJ
meetings_GER
powers_NN
of_PIN
the_DT
Company_NN
to_TO
borrow_VB
money_NN
._.
Annual_JJ
general_JJ
meetings_GER
and_CC
extraordinary_JJ
Variation_NOMZ
of_PIN
these_DEMP
borrowing_VBG
powers_NN
would_PRMD
general_JJ
meetings_GER
where_RB
a_DT
special_JJ
resolution_NOMZ
require_VPRT [SUAV]
the_DT
passing_GER
of_PIN
a_DT
special_JJ
resolution_NOMZ
of_PIN
is_VPRT
to_TO
be_VB [PASS]
passed_VBN
or_CC
a_DT
Director_NN
is_VPRT
to_TO
be_VB [BEMA]
the_DT
Companys_NN
shareholders_NN
._.
appointed_VBN
require_VPRT [SUAV] [THATD]
21_CD
clear_JJ
days_NN
notice_VPRT [PRIV]
to_TO
Designed_VBN
by_PIN
Addison_NN
Corporate_NN
Marketing_GER
Ltd_NN
